|Investor Relations Overview|
|CryoLife will not attend the RBC Capital Markets Healthcare Conference|
Q4 2013 CryoLife, Inc. Earnings Conference Call (Replay)
02/20/14 at 10:00 a.m. ET
|Fortune Small Business|
Congratulates CryoLife for making the 2009 hot list of the fastest-growing firms in America!
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves. CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia. More >>
|Reconciliation for Certain Items|
|There are currently no events scheduled.|
|Most Recent SEC Filings||More >>|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.